Clinical trials: COVID-19 Pandemic
HER2-positive Breast Cancer
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
This single arm, multicenter study provides the pertuzumab and trastuzumab fixed-dose combination formulation for subcutaneous injection (PH FDC SC) administered at home by a home health nursing provider for patients with human…
- Trial name
- NCT04395508
- Testing
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
- Where
- 12 sites in United States
- Sponsor
- Genentech, Inc.
SARS-CoV-2 Infection
Burn Injuries During COVID-19 Pandemic and Its Influence on Length of Stay
Burn injuries were thought to be difficult to treat during the new corona virus epidemic. Our goal is to determine the risk factors that influence length of hospital stay (LOS) of burn injured patients during COVID -19 pandemic.
- Trial name
- NCT06330389
- Testing
- Burn Injuries Graft Surgery
- Where
- Qatar
- Volunteers
- 70 people
- Sponsor
- Hamad Medical Corporation
Covid19
Tableted COVID-19 Therapeutic Vaccine
Safety and immunogenicity one-month study in healthy individuals administered once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19.
- Trial name
- COVID-19 (NCT04380532)
- Testing
- V-SARS
- Where
- 2 sites in Canada, Mongolia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Immunitor LLC
COVID
The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic
Hong Kong public healthcare system is facing tremendous pressure under the COVID-19 pandemic. As the virus spread in Hong Kong, Hong Kong Sanatorium \& Hospital (HKSH) is one of the first private hospitals which immediately…
- Trial name
- COVID-19 (NCT04416061)
- Testing
- COVID 19 Diagnostic Test
- Where
- Hong Kong
- Volunteers
- 2,510 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Infection, Respiratory Tract
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
The aim of this study is to investigate whether vaccination of elderly with VPM1002 could reduce hospital admissions and/or severe respiratory infectious diseases in the SARS-CoV-2 pandemic .
- Trial name
- NCT04435379
- Testing
- VPM1002
- Where
- 12 sites in Germany
- Volunteers
- 2,038 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
COVID19
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Trial name
- NCT05175690
- Testing
- Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Pregnancy Related, Mothers
COVID-19 Vaccine Confidence Among Pregnant Women and Mothers
The purpose of this study is to assess the level of vaccine confidence and influencers among pregnant women and mothers of school-aged children during the COVID-19 pandemic.
- Trial name
- VCCOVID (NCT04694664)
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Pregistry
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
COVID-19 Pandemic
Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351
It is a single center, randomized, open-labeled, blind endpoint evaluation, exploratory clinical study to evaluate the safety and immunogenicity of bivalent vaccine V-01D-351 as a booster.
- Trial name
- COVID-19 (NCT05583357)
- Testing
- V-01D-351, CoronaVac
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19 Pandemic
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.
- Trial name
- NCT05144139
- Testing
- COVID-19 mRNA vaccine
- Where
- Laos
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
COVID-19 Pandemic
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety…
- Trial name
- NCT05305300
- Testing
- PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A, PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B
- Where
- United Arab Emirates
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
COVID-19, Coronavirus Disease 2019
SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study
SARS-CoV-2 Nucleic Acid Detection Kit is an In Vitro Diagnostic (IVD) medical device intended for RNA detection of SARS-CoV-2 in human specimens using multiplex real-time polymerase chain reaction (RT-PCR) technology.
- Conditions
- COVID-19, Coronavirus Disease 2019, COVID-19 Pandemic, Diagnoses Disease
- Trial name
- CPS CW008 (NCT05492227)
- Testing
- Left-overs
- Where
- Spain
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- TransGen Biotech Co., LTD
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine…
- Trial name
- COVID-19 (NCT05096832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01), Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- Where
- 18 sites in Malaysia, Pakistan
- Volunteers
- 10,381 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19
Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.
- Trial name
- NCT04349592
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- Qatar
- Volunteers
- 456 people
- Sponsor
- Hamad Medical Corporation
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077332
- Testing
- Famotidine, Celecoxib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
COVID-19 Pandemic
Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen that causes a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19), which is spreading all over the world.
- Trial name
- NCT05366296
- Testing
- A Lyophilized COVID-19 mRNA Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wuhan Recogen Biotechnology Co., Ltd.
COVID-19, SARS-CoV-2
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05260437
- Testing
- CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg)
- Where
- 24 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Kidney Diseases, COVID-19 Infection
COVID-19 Among Children With Chronic Renal Diseases in Qatar
Coronavirus disease 2019 is a novel viral disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 virus. The original cases occurred in Wuhan, China, in December 2019 and rapidly spread to other areas worldwide…
- Conditions
- Chronic Kidney Diseases, COVID-19 Infection, Acute Kidney Injury, Chronic Renal Failure in Children
- Trial name
- CCCRDQ (NCT05275595)
- Testing
- Medical records review
- Where
- Qatar
- Volunteers
- 1,300 people
- Sponsor
- Hamad Medical Corporation